Small interfering RNA targeting nuclear factor kappa B to prevent vein graft stenosis in rat models

Transplantation Proceedings

Volumn 45, Issue 6, 2013, Pages 2553-2558

  Meng, X B ^a   Bi, X L ^a   Zhao, H L ^a   Feng, J B ^a   Zhang, J P ^a   Song, G M ^a   Sun, W Y ^a   Bi, Y W ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL WALL; CELL PROLIFERATION; CONTROLLED STUDY; EXTERNAL JUGULAR VEIN; GEL; GENE SILENCING; IN VIVO STUDY; MALE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; RAT; STENOSIS; VEIN GRAFT; VEIN GRAFT STENOSIS;

ANIMALS; CELL PROLIFERATION; CHEMOKINE CCL2; CONSTRICTION, PATHOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC THERAPY; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; JUGULAR VEINS; KI-67 ANTIGEN; MALE; NEOINTIMA; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84882247773     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.03.045     Document Type: Article

References (29)

1. P. Parang, and R. Arora Coronary vein graft disease: pathogenesis and prevention Can J Cardiol 25 2009 e57 e62
2. J.H. Shuhaiber, A.N. Evans, and M.G. Massad Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery Eur J Cardiothorac Surg 22 2002 387 396
3. V. Toprak, B.H. Sirin, and D. Tok The effect of cardiopulmonary bypass on the expression of inducible nitric oxide synthase, endothelial nitric oxide synthase, and vascular endothelial growth factor in the internal mammary artery J Cardiothorac Vasc Anesth 20 2006 63 67
4. T. Collins, and M.I. Cybulsky NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107 2001 255 264
5. E. Corrado, M. Rizzo, and G. Coppola An update on the role of markers of inflammation in atherosclerosis J Atheroscler Thromb 17 2010 1 11
6. K. Van der Heiden, S. Cuhlmann, and A. Luong le Role of nuclear factor kappaB in cardiovascular health and disease Clin Sci (Lond) 118 2010 593 605
7. M.P. de Winther, E. Kanters, and G. Kraal Nuclear factor kappaB signaling in atherogenesis Arterioscler Thromb Vasc Biol 25 2005 904 914
8. K. Shrey, A. Suchit, and M. Nishant RNA interference: emerging diagnostics and therapeutics tool Biochem Biophys Res Commun 386 2009 273 277
9. L. Aagaard, and J.J. Rossi RNAi therapeutics: principles, prospects and challenges Adv Drug Deliv Rev 59 2007 75 86
10. J. Wang, K. Liu, and L. Shen Small interfering RNA to c-myc inhibits vein graft restenosis in a rat vein graft model J Surg Res 169 2011 e85 e91
11. X.P. He, X.X. Li, and Z.H. Wang Transfection of hairpin small interfering RNA expression vector targeting rat nuclear factor (NF) (kB) inhibits rat cell proliferation induced by NF-kB signal pathway activation Transplant Proc 42 2010 4633 4637
12. X.P. He, X.X. Li, and Y.W. Bi The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model Transplant Proc 40 2008 1722 1726
13. J. Wu, and C. Zhang Neointimal hyperplasia, vein graft remodeling, and long-term patency Am J Physiol 297 2009 H1194 H1195
14. K. Hinokiyama, G. Valen, and S. Tokuno Vein graft harvesting induces inflammation and impairs vessel reactivity Ann Thorac Surg 82 2006 1458 1464
15. N.A. Scott Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury Adv Drug Delivery Rev 58 2006 358 376
16. S. Kwei, G. Stavrakis, and M. Takahas Early adaptive responses of the vascular wall during venous arterialization in mice Am J Pathol 164 2004 81 89
17. J.G. Motwani, and E.J. Topol Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention Circulation 97 1998 916 931
18. N. Shimizu, N. Azuma, and T. Nishikawa Effect on vein graft intimal hyperplasia of nuclear factor-kB decoy transfection using the second generation of HVJ vector J Cardiovasc 48 2007 463 470
19. T. Miyake, M. Aoki, and S. Shiraya Inhibitory effects of NF kappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model J Mol Cellur Cardiol 41 2006 431 440
20. R. Gareus, E. Kotsaki, and S. Xanthoulea Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis Cell Metab 8 2008 372 383
21. S. Yoshimura, R. Morishita, and K. Hayashi Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element "decoy" of nuclear factor-kappaB binding site as a novel molecular strategy Gene ther 8 2001 1635 1642
22. C. Monaco, E. Andreakos, and S. Kiriakidis Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis Proc Nat Acad Sci U S A 101 2004 5634 5639
23. P. Libby, Y. Okamoto, and V.Z. Rocha Inflammation in atherosclerosis: transition from theory to practice Circ J 74 2010 213 220
24. G. Pesarini, A. Amoruso, and V. Ferrero Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans Atherosclerosis 211 2010 242 248
25. J.N. Wilcox, N.A. Nelken, and S.R. Coughlin Local expression of inflammatory cytokines in human atherosclerotic plaques J Atheroscler Thromb 1 Suppl 1 1994 S10 S13
26. M.H. Eslami, S.P. Gangadharan, and M. Belkin Monocyte adhesion to human vein grafts: a marker for occult intraoperative injury? J Vasc Surg 34 2001 923 929
27. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
28. S. Xanthoulea, D.M. Curfs, and M.H. Hofker Nuclear factor kappa B signaling in macrophage function and atherogenesis Curr Opin Lipidol 16 2005 536 542
29. T. Wang, X. Zhang, and J.J. Li The role of NF-kappaB in the regulation of cell stress responses Int Immunopharmacol 2 2002 1509 1520